Summary: In 1,879 adults with type 2 diabetes participating in the SURPASS-2 phase 3 trial conducted across 128 sites in…
Browsing: Tirzepatide
Summary: In adults with early-onset type 2 diabetes (T2D) compared to those with later-onset T2D in a post hoc analysis…
Summary: In adults with long-standing type 2 diabetes inadequately controlled, subcutaneous tirzepatide, a dual agonist of GIP and GLP-1 receptors…
In patients with heart failure with preserved ejection fraction (HFpEF) and obesity, tirzepatide significantly reduced the composite risk of cardiovascular death or worsening heart failure and improved health status compared to placebo, though it was associated with higher gastrointestinal side effects.
In adults with moderate-to-severe obstructive sleep apnoea (OSA) and obesity, tirzepatide significantly reduced the apnea-hypopnea index (AHI) and body weight compared to placebo, with notable improvements in sleep-related outcomes and cardiovascular risk factors, albeit with increased gastrointestinal side effects.